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Summary In leprosy control there is a renewed interest in active case finding, which
is increasingly being combined with chemoprophylactic interventions to try and
reduce M. leprae transmission. The Leprosy Post-Exposure Prophylaxis (LPEP)
programme, currently ongoing in eight endemic countries, pilots the provision of
single-dose rifampicin (SDR) to eligible contacts of leprosy patients. LPEP has
developed a surveillance system including data collection, reporting and regular
monitoring for every participating country. This system is still largely programme-
specific to LPEP. To facilitate continuity after completion of the project phase and
start-up in other interested countries, we aim at identifying the minimal set of data
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required to appropriately document contact tracing activities and SDR administration
for leprosy control in a routine setting.
We describe four indicators for the index case (plus four already routinely
collected) and seven indicators for household/neighbour screening, and community
surveys. We propose two generic forms to capture all relevant information required at
field and district level to follow-up on individuals or data if needed, provide guidance
on the sequence of tasks, provide quality control by listing key questions to assess
SDR eligibility, and facilitate reporting. These generic forms have to be adapted to
local requirements in terms of layout, language, and additional operational indicators.
Introduction
Leprosy control is currently benefiting from a renewed interest in active case finding.1,2 These
efforts are increasingly being combined with chemoprophylactic interventions3 in the context
of a push to reduce Mycobacterium leprae transmission.4 The tracing of contacts of newly
identified leprosy patients, their screening for signs and symptoms of the disease and the
provision of single-dose rifampicin (SDR) to eligible contacts, are the key activities related
to chemoprophylaxis in the context of leprosy control, and of the Leprosy Post-Exposure
Prophylaxis (LPEP) programme.5 For the purpose of this programme, a surveillance system
including data collection, reporting and regular monitoring has been developed for every
participating country. While this system is aligned with the routine leprosy data collection, it
is still a programme-specific system to satisfy the needs of the programme in terms of
reporting and evidence generation to document the feasibility and impact of the LPEP
approach.
The LPEP programme includes 3 years of field work in each of the eight participating
countries (Brazil, Cambodia, India, Indonesia, Myanmar, Nepal, Sri Lanka, and Tanzania).
After completion of the field work phase, countries are encouraged to continue contact tracing
and SDR administration in the project area. A country may opt to extend the project phase,
expand the intervention to additional pilot areas, or roll out the intervention nationally,
depending on the strength of the evidence resulting from the programme, the confidence the
national leprosy control programme has in the possible impact of the intervention, and the
availability of resources. While some countries have already integrated chemoprophylaxis
into their national strategy to control leprosy,6 other countries may also require a specific
endorsement of the intervention by the World Health Organization (WHO) and the Global
Leprosy Programme. Currently, the Global Leprosy Programme recommends contact tracing
to facilitate early case detection, while calling for further research to determine the value of
prophylactic treatment.2
To facilitate continuity after completion of the project phase and start-up in other
interested countries, here, we aim at identifying the minimal set of data required to
appropriately document contact tracing activities and SDR administration for leprosy control
in a routine setting. Our recommendations are based on experience from the LPEP
programme and are designed to satisfy standard data needs, but we recognise that countries
may want to collect additional data to satisfy specific purposes or interests.
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DEFINITIONS AND CONSIDERATIONS
The definitions, indicators and generic forms presented below are together referred to as the
minimal essential data to document contact tracing and SDR for leprosy control in a routine
setting (‘minimal essential data’). They have been identified and designed based on standard
principles for public health data collection and reporting, practical experience from the LPEP
programme,5 and available guidance from the Global Leprosy Programme.7 In an iterative
process, the minimal essential data set has been reviewed by stakeholders in endemic
countries, different non-governmental organisations (NGOs) supporting leprosy control in
these countries, donor organisations, and members of the LPEP steering committee.
A subgroup of the Technical Advisory Group (TAG) of the Global Leprosy Programme,
which reports on information systems and monitoring annual progress towards targets, was
also consulted.
Household and neighbour contacts
In line with the available evidence, we encourage and advise a broad definition of household
contacts to maximize the impact of contact tracing and SDR.8 When identifying household
contacts, a definition should be chosen that is appropriate for the local conditions (e.g. people
living in the same apartment/house/compound, extended family unit/sharing essential
resources, etc.). Neighbour contacts include the households (typically around five) living
immediately adjacent to the household where the index patient resides. As with household
contacts, a definition for neighbour contacts should be chosen that is appropriate for the local
situation. A focus on household and neighbour contacts requires disclosure – and therefore
consent – of the index patient.9 Operationally, an effort to trace household and neighbour
contacts and screen them follows the diagnosis of an individual case. While available
evidence does not point towards an ‘optimal’ time point to trace household and neighbour
contacts,10 all epidemiological and operational considerations suggest that contact tracing
should be done between 1 and 6 months after the index patient started multi-drug therapy.
While early contact tracing reduces the risk that contacts themselves develop leprosy and
thereby also helps reducing delays in diagnosis and the risk of developing disabilities,
operational considerations may favour a periodic effort to trace the contacts of all index
patients diagnosed over a certain period (e.g. a quarter or half a year) in a campaign-style
effort, sometimes labelled a ‘drive’.10
Community contacts
Under certain conditions (e.g. a child leprosy case with disability, a child leprosy case in a
low burden setting, populations that are hard to reach, high case detection rate in a small
geographical setting), a full community screening should be considered.9 A community may
be defined as a neighbourhood, village, island population, school, workplace, etc., depending
on the local conditions and the socio-demographic characteristics of the new leprosy case(s)
(e.g. school child, factory worker, etc.). The size of the targeted community needs to be
carefully defined for each individual community screening effort, taking into consideration
the epidemiological situation, resources (funding, personnel, and time), logistics and
acceptability by the community of the intervention. A focus on community contacts means
that there is no need for disclosure and consent of the index patient. Rather, the community
J.H. Richardus et al.4
members should be informed that their area is endemic for leprosy or that leprosy cases have
been found in the community over the past years, and that a survey is planned to find any
remaining hidden cases.
The decision to screen a community should always take into account the number of index
patients in an area, over time. An ideal basis for such a decision is continuous mapping of
historical and current patients,11 and a periodic review of the spatial distribution of cases that
have emerged over a certain period, typically 1-5 years. Furthermore, every community
screening must be accompanied by an information campaign to raise awareness for leprosy
and the cardinal signs of the disease, and to address stigma.
Data
The focus of the effort described here, namely to define the minimal essential data required to
appropriately document contact tracing and SDR for leprosy control in a routine setting, is on
reporting to the national and international level. Underlying documentation at field level must
be more detailed to facilitate the work of the field staff and satisfy local operational, reporting
and follow-up needs, which usually implies that the current place of residence and detailed
contact information is recorded. This distinction is also reflected in the difference between the
generic forms and the suggested indicators for reporting.
Index patient (case)
With regard to the index patient, often referred to as the index case, we assume that basic
indicators are collected as required for reporting to the WHO Global Leprosy Programme
(age, sex, leprosy classification, and disability grade).7 In addition to these standard
indicators, we propose the collection and reporting of the following four key indicators:
1. Mode of detection.
This indicator is highly relevant as it is the only measure of contact tracing
effectiveness in terms of new leprosy patients detected.
+ Passive (includes self-reported, referral – by medical service or from outside
the health district, etc.).
+ Active (includes household and neighbour screening, community survey/
leprosy elimination campaigns (LEC), etc.).
2. Previous SDR.
This indicator is of key relevance to (indirectly and retrospectively) measure SDR
effectiveness. It refers to SDR previously given, e.g. after a household screening or in
the frame of a community survey, irrespective of the time when SDR had been given.
It can be reported in a simple Yes/No manner.
3. Presence of contacts in the current place of residence.
‘Current place of residence’ of the newly diagnosed leprosy patient can refer to the
household, but also a dormitory, boarding school etc., irrespective of the duration of
residency. The intention is to identify patients without household contacts in the
health district who therefore do not require follow-up or are difficult to trace. This is
an operational indicator, but should be reported as it contributes to the calculation of
the denominator to determine contact tracing coverage (% of new patients followed
up by contact tracing). It can be reported in a simple Yes/No manner.
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4. Index patient consent to disclosure and household/neighbour contact screening.
This is an operational indicator but should be reported as it contributes to the
calculation of the denominator to determine contact tracing coverage (% of new
patients who agreed to follow up by contact tracing). Also, it is an indicator for
acceptability of household/neighbour contact tracing. It can be reported in a simple
Yes/No manner.
To facilitate data collection, these indicators should be integrated into the basic leprosy
cards/forms used in nearly all programmes to summarise the basic information about a
leprosy patient.
Household and neighbour contact screening
We propose the collection and reporting of seven indicators related to household and
neighbour contact screening (Table 1):
1. Contacts listed/enumerated.
This is the denominator to calculate the contact tracing rate (% of reported contacts
actually traced).
2. Contacts traced.
This is the numerator to calculate the contact tracing rate. The denominator is the
number of contacts listed/enumerated (1) – the difference is due to absence of
contacts, and may be used to monitor the coverage of the contacts.
3. Contacts screened.
This is the numerator to calculate the contact screening rate. The denominator is the
number of contacts traced (2) – the difference is due to refusal to be screened, and
may be used to monitor the acceptability of the intervention.
4. Leprosy cases confirmed or suspected.
This indicator quantifies the outcome of the screening in terms of the number of
contacts that are confirmed or suspected of having leprosy. The number of confirmed
Table 1. Summary of the proposed minimal set of indicators to document contact tracing and post-exposure
prophylaxis in leprosy control. All indicators are to be reported as totals and can be stratified by sex
Index case Household and neighbour screening Community survey
Age (child/adult) Number listed/enumerated* Number estimated0
Sex (M/F) Number traced Number traced
Leprosy classification (PB/MB) Numbers screenedþ Numbers screenedþ
Disability grade (G2D) Number confirmed or suspected Number confirmed or suspected
Mode of detection (passive/active) Number SDR excluded Number SDR excluded
Previous SDR (yes/no) Number SDR refused Number SDR refused
Presence of contacts (yes/no) Number SDR received Number SDR received
Consent to disclosure (yes/no)
*Contacts listed ¼ contacts screenedþ (contacts absentþ screening refusedþ contacts receiving MDT or have
received in the past 2 years)
0Ideally based on available listing. If no listing available, then estimate
þContacts screened ¼ Leprosy suspects þ SDR refused þ SDR excluded þ SDR received
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or suspected leprosy cases may be used to calculate additional indicators for in-depth
analysis of contact tracing (e.g. new confirmed or suspected cases per x contacts
screened, new confirmed or suspected cases per index case etc.). Confirmation is
sometimes made on the spot during screening if a qualified health worker is present,
but very often follows later, when the suspected contact is seen in a health clinic and
further examined. Under such circumstances, the final diagnosis of each suspected
leprosy case should be retrieved from the leprosy register. Finally, it is assumed that
all known leprosy cases among the targeted contacts that are currently on MDT are
exempted from screening.
5. SDR excluded/contraindicated.
This is the numerator to calculate the SDR exclusion rate. Denominator is the number
of contacts screened (3). This indicator may be used to monitor the coverage of this
high-risk population with preventive chemotherapy.
6. SDR refused.
This is the numerator to calculate the SDR refusal rate. Denominator is the number of
contacts screened (3) minus the number of SDR excluded/contraindicated (5). This
indicator may be used to monitor the coverage of this high-risk population and the
acceptability of the intervention.
7. SDR received.
This is the numerator to calculate the SDR coverage rate. Denominator is the number
of contacts screened (3). This indicator may be used to monitor the coverage of this
high-risk population with preventive chemotherapy.
Community survey
We also propose the collection and reporting of seven indicators related to community
surveys (Table 1):
1. Community members estimated.
This is the denominator to calculate the tracing rate (% of estimated population
actually traced).
2. Contacts traced.
This is the numerator to calculate the contact tracing rate. The denominator is the
estimated number of community members (1) – the difference is due to absence of
community members, and may be used to monitor the coverage of the contacts.
3. Contacts screened.
This is the numerator to calculate the contact screening rate. The denominator is the
number of contacts traced (2) – the difference is due to refusal to be screened, and
may be used to monitor the acceptability of the intervention.
4. Leprosy cases confirmed or suspected.
This indicator quantifies the outcome of the screening in terms of the number of
contacts that are confirmed or suspected of having leprosy. The number of confirmed
or suspected leprosy cases may be used to calculate additional indicators for in-depth
analysis of contact tracing (e.g. new confirmed or suspected cases per x contacts
screened, new confirmed or suspected cases per index case etc.). Confirmation is
sometimes made on the spot during screening if a qualified health worker is present,
but very often follows later, when the suspected contact is seen in a health clinic and
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further examined. Under such circumstances, the final diagnosis of each suspected
leprosy case should be retrieved from the leprosy register. Finally, it is assumed that
all known leprosy cases that are currently on MDT in the area are exempted from
screening.
5. SDR excluded/contraindicated.
This is the numerator to calculate the SDR exclusion rate. Denominator is the number
of community members screened (3). This indicator may be used to monitor the
coverage of the population with preventive chemotherapy.
6. SDR refused.
This is the numerator to calculate the SDR refusal rate. Denominator is the number of
community members screened (3) minus the number of SDR excluded/contraindi-
cated (5). This indicator may be used to monitor the coverage of the population and
acceptability of the intervention.
7. SDR received.
This is the numerator to calculate the SDR coverage rate. Denominator is the number
of community members screened (3). This indicator may be used to monitor the
coverage of the population with preventive chemotherapy.
The indicators suggested above are collected at field level. Summary data per household
are usually reported to the district/municipality, where they are then aggregated for the
district and either directly submitted to the central level or to further intermediate levels
(e.g. province/state) where aggregation may happen again before submission to the
national level.
In the case of a community survey, there is no equivalent to a contact list and there is no
need to embark on a census if no register data is available. Instead, the number of individuals
in the target community should be estimated. However, in many cases a list that can be used
will be available (e.g. for schools and factory workers, in some countries village lists are
maintained, etc.). Thus, community survey activities can be documented on a form that is
derived from the form used for household screening. Of note, that form is best used for the
lowest unit of organisation of the community that is surveyed (e.g. household, school class,
work team, etc.). Summary data for each community survey are reported to the
district/municipality, which may then be aggregated for the district and province/state etc.,
as appropriate, before submission to the national level.
Forms
We propose two generic forms for the recording of household/neighbour contact screening
activities and community surveys, respectively. The forms are inspired by the LPEP contact
forms,5 and designed to capture all relevant information required at district/municipality level
to follow-up on individuals or data in case this is needed, provide guidance on the sequence of
tasks, provide quality control by listing key questions to assess SDR eligibility, and facilitate
reporting. See Figures 1 (household and neighbour contacts) and 2 (community screening) for
generic versions of these forms, which need to be adapted to local requirements in terms of
layout, language, additional operational indicators, etc.
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Discussion
Contact tracing should be a cornerstone of the leprosy control strategy of leprosy endemic
countries. Several countries have also integrated chemoprophylaxis into their national
leprosy elimination strategy, or are in the process of doing so, while others are piloting the
approach.6 Consequently, countries may already have integrated a part or all of these
indicators into their data collection system. For example, countries already implementing
contact tracing usually have a system to capture relevant data.
Pilot interventions often operate stand-alone recording and reporting systems. Every
country proceeding to integrate an intervention that resembles LPEP in its routine leprosy
control activities will need to modify its leprosy recording and reporting system to capture
relevant activities and report key programmatic and outcome indicators to the national level.
Also, monitoring activities will need to be adjusted to cover these additional activities. As it is
the case with every reporting system, a balance must be found between the desire for detail
and the burden created by recording and reporting. The resulting recording and reporting
system for contact tracing and SDR administration should be fully integrated into the national
leprosy reporting system, as the intervention has been integrated into the national strategy to
control and eliminate leprosy. This will avoid duplication of efforts, reduce costs and signal
the routine character of the activities to the field staff and the health system at large.
Ideally, the leprosy data collection system is updated to collect the additional indicators
required for the surveillance of contact tracing and chemoprophylaxis along with the
introduction of the actual activities in the field-level routine. The parallel updating of the
activity protocols and data collection system allows for integrated training and avoids
confusion about recording and reporting needs pertaining to the new activity. Also,
integration from the outset allows the use of system-generated data to monitor the
acceptability of the new interventions among the population and health workers through, for
example, time trends in coverage and participation.
Governments may be reluctant to incorporate more information into their national disease
control reporting system. An important argument in favour would be that if a government
actually decides to add contact surveys and any other (prophylactic) interventions to their
leprosy control programme, quality control dictates that these activities are monitored
adequately. In addition, there may be other arguments specific for a country that should be
addressed separately. If the Global Leprosy Programme proceeds to officially endorse or
recommend preventive chemotherapy,7 changes in the final list of indicators may occur.
However, such changes will likely be minor and tweaking an established data collection
system should be easier than establishing a new one under the pressure of international
reporting demands.
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